Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $117.00 at BTIG Research

Monopar Therapeutics (NASDAQ:MNPR) had its price target boosted by equities research analysts at BTIG Research from $104.00 to $117.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 23.73% from the stock’s previous close.

Several other equities analysts also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $105.00 price objective on shares of Monopar Therapeutics in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. UBS Group set a $105.00 price target on shares of Monopar Therapeutics in a research note on Monday. Finally, Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $108.75.

Monopar Therapeutics Trading Up 7.8%

Shares of NASDAQ MNPR opened at $94.56 on Tuesday. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $105.00. The stock has a 50 day moving average of $62.99 and a 200-day moving average of $62.16. The company has a market capitalization of $633.55 million, a P/E ratio of -49.77 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. Analysts predict that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets grew its stake in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Monopar Therapeutics in the fourth quarter valued at about $65,000. Caitong International Asset Management Co. Ltd bought a new position in Monopar Therapeutics during the fourth quarter worth about $86,000. Finally, JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.